The__O Cardiff-led__B-MISC programme__O has__O defined__O the__O standard__O of__O care__O for__O AHA__B-ORG internationally.__O
This__O is__O evidenced__O by__O the__O new__O national5.2__O and__O international5.3,5.4__O treatment__O guidelines__O for__O AHA__B-ORG that__O have__O been__O written__O (led__O by__O Collins__B-ORG in__O Cardiff__B-LOC with__O Angela__B-LOC Huth-Kuhne__I-LOC in__O Germany),__B-LOC based__O on__O novel__O data__O generated__O by__O Cardiff-led__O research3.1-3.6,__O that__O for__O the__O first__O time__O allow__O evidence-based__O treatment__O of__O AHA.__B-LOC
Our__B-PER All-Wales3.1__I-PER and__O UK3.2__O studies__O initiated__O this__O process__O prior__O to__O the__O REF__B-ORG impact__O period,__O forming__O the__O basis__O of__O UK__B-LOC national__O guidelines__O in__O 20065.1__O (150__O citations).__O
Missing__O information__O in__O the__O 2006__O guidelines__O was:__O Data__O about__O the__O relative__O efficacy__O of__O available__O immunosuppressive__O regimens__O to__O eradicate__O the__O factor__O VIII__B-ORG inhibitors__O in__O matched__O patients__O Comparison__O of__O the__O efficacy__O of__O haemostatic__O treatments__O to__O treat__O bleeds__O in__O matched__O patients.__O
Information__O about__O the__O high__O frequency__O of__O diagnostic__O delay.__O
Information__O about__O the__O incidence__O of__O thrombotic__O complications__O of__O haemostatic__O agents__O Over__O the__O REF__B-ORG period,__O further__O data__O from__O the__O European__B-MISC study3.3-3.6__O led__O to__O the__O UK__B-LOC guidelines__O being__O substantially__O changed__O and__O updated__O in__O 20135.2,__O a__O process__O co-ordinated__O by__O The__O UK__B-ORG Haemophilia__I-ORG Centre__I-ORG Directors'__I-ORG Organisation__I-ORG (UKHCDO)__I-ORG Inhibitor__I-ORG Working__I-ORG Party__I-ORG chaired__O by__O Collins__B-ORG of__I-ORG Cardiff__I-ORG University.__O
These__O guidelines__O have__O been__O endorsed__O by__O the__O British__B-ORG Committee__I-ORG on__O Standards__O in__O Haematology,__O UKHCDO__O and__O British__B-ORG Society__I-ORG of__O Haematology.__B-LOC
Of__O the__O 18__O specific__O management__O recommendations__O on__O AHA__B-ORG in__O the__O 2013__O guideline5.2,__O 14__O are__O underpinned__O by__O evidence__O produced__O by__O the__O Cardiff-led__B-ORG research__O programme.__O
The__O guidelines__O have__O been__O agreed__O and__O adopted__O by__O the__O English__B-MISC Specialised__B-ORG Commissioning__I-ORG Group__I-ORG (The__I-ORG Haemophilia__I-ORG Clinical__I-ORG Reference__I-ORG Group)__I-ORG which__O has__O directed__O that__O all__O 90__O UK__B-LOC haemophilia__O centres__O must__O follow__O UKHCDO__B-ORG guidelines.__O
The__O Cardiff-led__B-MISC research__O programme__O has__O also__O resulted__O in__O the__O production__O of__O two__O international__O guidelines5.3,5.4__O as__O collaborations__O between__O Cardiff__B-ORG University__I-ORG and__O European,__B-LOC north__O American__B-MISC and__O Japanese__B-MISC colleagues.__O
These__O guidelines__O have__O been__O adopted__O worldwide__O and__O are__O the__O most__O cited__O papers__O in__O the__O field__O since__O 2009__O (90__O citations);__O they__O have__O been__O cited__O by__O groups__O from__O Europe,__B-LOC north__I-LOC and__O south__O America,__B-PER India,__I-PER Korea__B-LOC and__O Japan__B-LOC as__O accepted__O standard__O practice.__O
Recommendations__O in__O clinical__O guidelines__O and__O treatment__O protocols__O based__O on__O Cardiff-led__B-MISC research__O RECOGNITION__B-ORG AND__O DIAGNOSIS__B-ORG 1.__O
Novel__O finding:__O Significant__O diagnostic__O delay__O is__O common__O even__O after__O abnormal__O clotting__O tests__O have__O been__O found__O (European__B-MISC study)3.3__O New__B-MISC treatment__O recommendation:__O Laboratories__B-ORG should__O investigate__O abnormal__O clotting__O tests__O for__O AHA__B-ORG even__O if__O the__O referring__O clinician__O had__O not__O requested__O them__O and__O haematologists__O should__O directly__O inform__O clinicians__O of__O the__O implications__O of__O results5.2-5.4__O 2.__O
Novel__O finding:__O Delay__O in__O recognition__O of__O symptoms__O of__O AHA__B-ORG (European__I-ORG study)3.3__O Action:__B-ORG Typical__I-ORG presentations__O highlighted__O in__O management__O guidelines__O aimed__O at__O general__O clinicians5.2-__O 5.4__O 3.__O
Novel__O finding:__O Fatal__B-MISC bleeding__O may__O occur__O up__O to__O 6__O months__O after__O diagnosis__O if__O inhibitor__O is__O not__O eradicated__O (UK__O study)3.2__O New__O treatment__O recommendation:__O refer__O to__O specialist__O centres__O to__O start__O immunosuppression__O as__O soon__O as__O the__O diagnosis__O is__O made__O even__O if__O presentation__O appears__O benign5.2-5.4__O TREATMENT__B-ORG 4.__O
Novel__O finding:__O Combined__O steroids__O and__O cyclophosphamide__O result__O in__O a__O higher__O stable__O remission__O rate__O than__O steroids__O alone__O and__O rituximab__O confers__O no__O additional__O benefit__O (European__B-MISC study)3.4__O New__B-MISC treatment__O recommendation:__O Recommended__B-ORG first__O line__O immunosuppression__O protocol__O changed__O between__O the__O 2006__O and__O 2013__O UK__B-LOC guidelines__O and__O rituximab__O to__O be__O reserved__O for__O second__O line__O therapy.5.2__O 5.__O
Novel__O finding:__O There__O is__O a__O high__O incidence__O of__O relapse__O after__O immunosuppression__O has__O been__O stopped__O (UK__O and__O European__B-MISC studies)3.2,3.4__O New__B-MISC treatment__I-MISC recommendation:__O Longer__O (at__O least__O one__O year)__O and__O more__O intensive__O follow__O up__O is__O required__O in__O specialist__O clinics5.2-5.4__O SAFETY__O 6.__O
Novel__O finding:__O There__O is__O significant__O morbidity__O and__O mortality__O associated__O with__O immunosuppressive__O regimens__O (UK__O and__O European__B-MISC studies)3.2,3.4__O New__B-MISC treatment__O recommendation:__O Immunosuppressive__B-ORG protocols__O adapted__O to__O take__O the__O age__O and__O co-__O morbidity__O of__O patients__O into__O account5.2-5.4__O 7.__O
Novel__O finding:__O The__O two__O available__O inhibitor__O bypassing__O agents__O are__O equally__O as__O effective__O for__O controlling__O bleeds__O but__O both__O are__O better__O than__O factor__O VIII__B-MISC (European__I-MISC study)3.5__O New__B-MISC treatment__O recommendation:__O Bypassing__B-MISC agents__O should__O be__O used__O as__O first__O line__O therapy__O to__O treat__O bleeds.5.2-5.4__O 8.__O
Novel__O finding:__O Iatrogenic__B-ORG bleeding__O is__O common__O following__O venepuncture,__O blood__O pressure__O monitoring__O and__O invasive__O procedures.__O
(UK__O study)3.2__O New__O treatment__O recommendation:__O Venepuncture__O and__O blood__O pressure__O monitoring__O should__O be__O kept__O to__O a__O minimum__O and__O invasive__O procedures__O postponed__O until__O factor__O VIII__B-ORG level__O has__O increased.5.2-5.4__O 9.__O
Novel__O finding:__O There__O is__O a__O high__O incidence__O of__O arterial__O and__O venous__O thrombotic__O side__O effects__O associated__O with__O treating__O AHA__B-ORG with__O bypassing__O agents__O (European__B-MISC study)3.5__O New__B-MISC treatment__O recommendation:__O Bypassing__O agents__O should__O only__O be__O used__O on__O the__O advice__O of__O specialist__O haemophilia__O centres.__O
Bypassing__O agents__O in__O AHA__B-ORG should__O not__O be__O used__O in__O combination__O or__O in__O high__O dose__O regimens__O licensed__O for__O congenital__O haemophilia5.2-5.4__O 10.__O
Novel__O finding:__O 25-30%__O of__O bleeds__O resolved__O without__O haemostatic__O treatment__O and__O these__O bleeds__O have__O characteristic__O features__O (UK__O and__O European__B-MISC studies)3.2,3.3,3.5__O New__B-MISC treatment__O recommendation:__O Withhold__B-MISC bypassing__O agents__O in__O certain__O types__O of__O bleeds__O to__O limit__O the__O risk__O of__O thrombotic__O complications.5.2-5.4__O Effect__O of__O research__O on__O measures__O of__O clinical__O outcomes__O The__O treatment__O guidelines__O have__O been__O disseminated__O to__O patient__O groups,__O clinicians__O specialising__O in__O haemostasis__O and__O general__O physicians__O around__O the__O world.__O
By__O ensuring__O they__O receive__O the__O most__O appropriate__O treatment__O and__O care,__O the__O recommendations__O impact__O on__O all__O patients__O with__O AHA.__B-ORG
The__O international__O guideline__O published__O in__O 2009,__O aimed__O at__O specialist__O haematologists__O working__O in__O tertiary__O referral__O centres,__O has__O been__O cited__O by__O groups__O from__O Europe,__B-LOC north__I-LOC and__O south__O America,__B-PER India,__I-PER Korea__B-LOC and__O Japan__B-LOC as__O accepted__O standard__O practice.__O
